Welcome to our dedicated page for Dr Reddys Labs SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dr. Reddy's Laboratories Limited (RDY) SEC filings page on Stock Titan brings together the company’s U.S. regulatory disclosures as a foreign private issuer listed on the New York Stock Exchange. Dr. Reddy's files reports such as Form 6-K with the Securities and Exchange Commission, providing investors with access to financial results, board and corporate actions, and other information furnished under its home-country requirements.
Key filing types for Dr. Reddy's include periodic Form 6-K submissions that often attach consolidated IFRS financial statements, segment data for Global Generics and Pharmaceutical Services and Active Ingredients (PSAI), and management commentary on revenue trends, R&D spending and regional performance. These filings can also include intimations regarding board meetings, corporate actions and other material updates first disclosed in India.
For a pharmaceutical manufacturer active in APIs, generics, branded generics, biosimilars and OTC products, SEC filings are a primary source for understanding segment performance, geographic mix and investment in R&D. Investors can use them to track how Dr. Reddy's generics and biosimilars portfolios evolve, how collaborations and acquisitions contribute to results, and how the company allocates capital across regions and product categories.
On Stock Titan, each new RDY filing from EDGAR is captured and organized chronologically. AI-powered summaries help explain the main points of lengthy documents, highlighting items such as revenue movements, margin changes, R&D focus areas and notable regulatory or ESG disclosures. Users can quickly scan these summaries before diving into the full text of a 6-K or related exhibits.
In addition to financial information, this page can surface filings that relate to governance, risk and compliance, complementing press releases about inspections, recalls or ESG recognitions. Together, these documents provide a structured view of Dr. Reddy's regulatory footprint in the U.S. and support deeper analysis of the RDY stock for research-oriented investors.
Dr. Reddy’s Laboratories Limited filed a Form 6-K to share an audio recording of its earnings call for the quarter ended December 31, 2025. The call was conducted on January 21, 2026, and the company has provided a web link to the full audio recording for investors and exchanges.
The notice has been sent to the National Stock Exchange of India, BSE, New York Stock Exchange, and NSE IFSC, underscoring that this is a formal communication of the recorded earnings discussion for regulatory and investor information purposes.
Dr. Reddy’s Laboratories Limited filed a Form 6-K as a foreign private issuer, providing an intimation dated January 21, 2026. The company has circulated a presentation on its unaudited financial results for the quarter ended December 31, 2025 to the National Stock Exchange of India, BSE, the New York Stock Exchange, and NSE IFSC.
The filing itself does not reproduce the financial figures, but formally records that these quarterly unaudited results have been prepared and shared with the stock exchanges for information and record purposes.
Dr. Reddy’s Laboratories reported steady growth for Q3FY26 and the nine months ended December 31, 2025. Consolidated Q3 revenues were ₹87,268 million, up 4.4% year-on-year but slightly lower sequentially, while 9MFY26 revenues reached ₹260,771 million, an 8% increase from the prior year. Growth was broad-based across India, Europe, Emerging Markets and PSAI, but North America declined mainly due to lower Lenalidomide sales and pricing pressure.
Profitability softened as the business mix shifted. Q3 gross margin fell to 53.6% from 58.7% a year earlier, and EBITDA margin declined to 23.5% from 27.5%. For 9MFY26, EBITDA was ₹66,787 million, down 1% year-on-year, and profit before tax was ₹52,826 million, down 7%, with profit attributable to equity holders essentially flat at ₹40,649 million. Diluted EPS for 9MFY26 was ₹48.78.
The company continues to invest in branded franchises and R&D, while noting one-time costs from changes in Indian labour codes. The balance sheet remains strong, with cash and investments of ₹87,191 million, loans and borrowings of ₹67,732 million, equity of ₹375,756 million, a net cash surplus of ₹30,677 million and an annualised RoCE of 20.4% as of December 31, 2025.
Dr. Reddy’s Laboratories reports stable results for the nine months ended December 31, 2025. Revenues rose to
Profit for the period was
The balance sheet remains strong with total assets of
FAQ
What is the current stock price of Dr Reddys Labs (RDY)?
What is the market cap of Dr Reddys Labs (RDY)?
